Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Avidity Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Avidity Biosciences, Inc.

RNA

Avidity Biosciences, Inc.

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs), a novel RNA therapeutic platform combining monoclonal antibodies with oligonucleotides to target disease-causing RNA. Focused on rare neuromuscular diseases like myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy, Avidity aims to deliver precise, scalable treatments addressing underlying genetic causes with improved tissue targeting and dosing convenience.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Avidity Biosciences, Inc.

1
1
Avidity Biosciences, Inc. Avidity Biosciences Reports $684.6 Million Net Loss and $18.8 Million Revenue for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Avidity Biosciences, Inc. Avidity Biosciences Reports Revenue Growth and Merger Agreement with Novartis

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Avidity Biosciences, Inc. Avidity Biosciences Reports Q2 2025 Financial Results with Increased Collaboration Revenue

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Avidity Biosciences, Inc. Avidity Biosciences Reports Q1 2025 Financial Results with Increased Losses and Decreased Collaboration Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Avidity Biosciences, Inc. Avidity Biosciences Reports Financial Developments, Increased Cash and Cash Equivalents, and Strategic Initiatives

Via official filing (AI summary) | over 1 year ago | 0 comments